<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889626</url>
  </required_header>
  <id_info>
    <org_study_id>Apa/Cap maintenance in GC</org_study_id>
    <nct_id>NCT03889626</nct_id>
  </id_info>
  <brief_title>The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer</brief_title>
  <official_title>A Phase III Study of Comparing the Maintenance Treatment of Apatinib, Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and tolerability of the maintenance
      treatment of Apatinib/Capecitabine after fluorouracil and platinum based first-line
      chemotherapy in advanced gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to now, whether maintenance therapy after first line treatment can bring survival benefits
      to patients with advanced gastric cancer is unknown, and let alone which drug is most
      suitable. Our study is designed to prove whether the maintenance treatment of Apatinib or
      Capecitabine are better than observation after fluorouracil/platinum based first-line
      chemotherapy in advanced gastric cancer
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 22, 2019</start_date>
  <completion_date type="Anticipated">March 22, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 22, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>six weeks</time_frame>
    <description>PFS is calculated from the time of randmization to disease progression or death whichever happen first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>six weeks</time_frame>
    <description>OS is calculated from the time of randmization to death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>six weeks</time_frame>
    <description>we will use EORTC QLQ-C30 to evaluate QoL.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>six weeks</time_frame>
    <description>we will use CTC AE4.0 to evaluate adverse events.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Stomach Diseases</condition>
  <condition>Digestive System Neoplasms</condition>
  <condition>Capecitabine</condition>
  <condition>Apatinib</condition>
  <condition>Neoplasms</condition>
  <condition>Molecular Mechanisms of Pharmacological Action</condition>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, patients will receive a daily oral treatment with Apatinib 500mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm , patients will receive capecitabine 1000mg/m2 twice for 14 days, and repeat every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In this arm, no additional treatment will be given, and patients will be followed up at regular time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib: 500mg qd po, q4w</description>
    <arm_group_label>Apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine: 1000mg/m2 bid po, d1-14, q3w</description>
    <arm_group_label>Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed advanced or metastatic gastric or gastroesophageal junction
             adenocarcinoma

          -  ECOG PS 0-2

          -  At least one measurable or evaluable lesion in the first-line chemotherapy

          -  The fist line treatment should be 5-FU based regimen (e.g.
             ECF/EOF/EOX/FOLFOX/XELOX/XP) , and patients should received 6 cycles (3-week regimen)
             or 12 cycles (2-week regimen) treatment with the efficacy of non-PD

          -  The time from the last cycle treatment to the enrollment cannot exceed 6 weeks

          -  Adequate hepatic, renal, heart, and hematologic functions (platelets ≥75×109/L,
             neutrophil ≥1.5×109/L, hemoglobin ≥80 g/L, serum creatinine ≤1.5mg/dl, total bilirubin
             ≤1.5mg/dl, and serum transaminase ≤2.5× the ULN)

        Exclusion Criteria:

          -  Received 2 or more regimens for palliative chemotherapy

          -  Pregnant or lactating women

          -  Concurrent cancer, or history of other malignancies except cured basal cell carcinoma
             of skin and carcinoma in-situ of uterine cervix

          -  Uncontrolled brain, or leptomeningeal involvement, complete intestinal obstruction

          -  Clinically significant active bleeding, OB 2+ or higher

          -  Patients with locally advanced gastric cancer who are scheduled to receive
             radiotherapy

          -  Clinically relevant coronary artery disease or a history of a myocardial infarction
             within the last 12 months or high risk/uncontrolled arrhythmia

          -  Uncontrolled significant comorbid conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>no younger than 18 year-old</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 17, 2019</study_first_submitted>
  <study_first_submitted_qc>March 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>March 23, 2019</last_update_submitted>
  <last_update_submitted_qc>March 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xiaodong Zhu</investigator_full_name>
    <investigator_title>Principal Investigator and Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Capecitabine</keyword>
  <keyword>Apatinib</keyword>
  <keyword>Maintenance Treatment</keyword>
  <keyword>Advance Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Stomach Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

